Search Results 261-270 of 12324 for Multiple myeloma red flag

1. A Study To Evaluate The Safety And Effectiveness Of Metformin And Nelfinavir With Bortezomib In Patients With Relapsed And/or Refractory Multiple Myeloma - Mayo Clinic

   ... multiple myeloma. Participation eligibility ... Hemoglobin ≥ 8.0 g/dL (No red cell transfusion should have been administered within 4 days of registration); ...

2. Hematology - Clinical trials

   This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or ...

3. Mayo Clinic researchers study potential new CAR-T cell therapy for multiple myeloma

   The trial tested B cell maturation antigen targeting CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), in patients with multiple myeloma who received ...

4. Panobinostat And Everolimus In Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, Or Hodgkin Lymphoma - Mayo Clinic

   Panobinostat And Everolimus In Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, Or Hodgkin Lymphoma · More about research at Mayo Clinic.

5. Study Comparing Daratumumab, Lenalidomide, And Dexamethasone With Lenalidomide And Dexamethasone In Participants With Previously Untreated Multiple Myeloma - Mayo Clinic

   Study Comparing Daratumumab, Lenalidomide, And Dexamethasone With Lenalidomide And Dexamethasone In Participants With Previously Untreated Multiple Myeloma.

6. Pragmatic Comparative Clinical Trial To Determine Optimal Initial Therapy For Multiple Myeloma

   ... Multiple Myeloma. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

7. A Study To Evaluate CB-839 HCl In Combination With Carfilzomib And Dexamethasone In Treating Patients With Recurrent Or Refractory Multiple Myeloma - Mayo Clinic

   Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma. Participation eligibility. Participant eligibility ...

8. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) - Mayo Clinic

   ... Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) ... multiple myeloma who were previously exposed to daratumumab intravenous ...

9. Dr. Fonseca Expands Myeloma Therapies to Treat Other Blood Disorders - Mayo Clinic

   “I'm a pathological optimist. Let's start with that,” says Dr. Rafael Fonseca. “When I began at Mayo Clinic in 1998, we had two drugs to treat multiple ...

10. A Study To Determine Recommended Dose, Regimen And Evaluate The Safety And Preliminary Effectiveness Of CC-92480 In Combination With Standard Treatments In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM) And Newly Diagnosed Multiple Myeloma (NDMM) - Mayo Clinic

    ... Multiple Myeloma (RRMM) And Newly Diagnosed Multiple Myeloma (NDMM). Print details. Share; Facebook · Twitter. Overview; Participation eligibility ...